Vicore Pharma (NASDAQ:VCRE) Announces Quarterly Earnings Results

Vicore Pharma (NASDAQ:VCRE) announced its quarterly earnings results on Thursday. The company reported ($0.04) EPS for the quarter, FiscalAI reports. The business had revenue of $0.06 million for the quarter.

Vicore Pharma Trading Up 7.3%

Shares of Vicore Pharma stock traded up $0.69 during trading on Thursday, hitting $10.13. 27,879 shares of the stock traded hands, compared to its average volume of 26,946. Vicore Pharma has a 52 week low of $7.88 and a 52 week high of $17.80.

Analyst Ratings Changes

Several research firms have weighed in on VCRE. Wall Street Zen raised Vicore Pharma to a “hold” rating in a report on Saturday, October 24th. Chardan Capital began coverage on Vicore Pharma in a report on Wednesday. They set a “buy” rating and a $15.00 price objective for the company. Weiss Ratings began coverage on shares of Vicore Pharma in a research report on Thursday, October 8th. They issued a “sell (e-)” rating on the stock. Finally, Jefferies Financial Group initiated coverage on shares of Vicore Pharma in a research note on Friday, October 9th. They issued a “buy” rating and a $25.00 target price on the stock. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $20.00.

About Vicore Pharma

Vicore Pharma is a Swedish clinical-stage biopharmaceutical company focused on developing treatments for severe respiratory diseases, particularly pulmonary fibrosis and other conditions involving lung injury and impaired tissue repair. The company is headquartered in Gothenburg, Sweden, and conducts research and clinical development activities aimed at addressing significant unmet medical needs.

Vicore’s lead drug candidate is buloxibutid, also known as C21, an oral small-molecule agonist of the angiotensin II type 2 receptor.